Ligand Pharmaceuticals (NASDAQ:LGND) Coverage Initiated at Stifel Nicolaus
Analysts at Stifel Nicolaus assumed coverage on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $143.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective points to a potential upside […]
Analysts at Stifel Nicolaus assumed coverage on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $143.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective points to a potential upside […]
